Two companies called Compass Pathways and Greenbrook TMS want to work together on a project. They are studying a special medicine made from a plant called psilocybin that might help people with mental health problems feel better. This medicine is not approved yet, but they hope it will be soon. The two companies will try different ways of giving this medicine to patients in the US if it gets approved. Read from source...

- The title is misleading and sensationalist, implying that psilocybin therapy is a breakthrough or the only solution for mental health treatment, while it is still an experimental and controversial treatment.
- The article does not provide enough context about the current state of mental health treatment, the prevalence and impact of different disorders, the limitations and challenges of existing approaches, and the potential risks and benefits of psilocybin therapy.
- The article focuses too much on the business aspects of the collaboration, such as the market size, revenue opportunities, and stock prices, rather than the scientific and medical aspects, such as the methodology, results, and implications of the research.
- The article uses vague and ambiguous terms, such as "psilocybin therapy", "investigational COMP360 psilocybin treatment", and "delivery models", without explaining what they mean or how they work.
- The article does not cite any sources, studies, or experts to support its claims or provide credibility to the information.